All In Biotech

Drug Trial Radar · NCT07804368

Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centers for Disease Control and Prevention; University of Alabama at Birmingham
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II platform trial will evaluate the safety, tolerability, and effectiveness of investigational antifungal agents as salvage or consolidation therapy in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis. The study will enroll adults who are receiving active antifungal therapy and who have intolerance, failure, or unavailability of standard first-line consolidation therapy. The first investigational agent evaluated in the platform trial is oteseconazole. Participants will receive study drug and complete follow-up assessments for symptom status, functional status, adverse events, laboratory safety, study drug discontinuation, and quality of life. Participants will be followed during therapy and for up to 6 months after therapy.

Conditions

  • Coccidioidomycosis
  • Blastomycosis
  • Histoplasmosis
  • Dimorphic Fungal Infection
  • Endemic Mycoses

Interventions

  • OteseconazoleDrug

    Participants will receive oral oteseconazole 600 mg twice daily for 12 days, followed by 600 mg weekly. Total treatment duration depends on diagnosis: up to 52 weeks for coccidioidomycosis, 26 weeks for blastomycosis, and 26 weeks for histoplasmosis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Symptom StatusTime frame: Baseline through 12 months
  2. Change in Functional StatusTime frame: Baseline through 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • Arizona State University - Tempe Campus

    Tempe, Arizona

  • University of California, Davis

    Davis, California

  • UCSF Fresno

    Fresno, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.